NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.81% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.60% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 4.59% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 4.49% |
| MRUS | Merus BV | Healthcare | Biotechnology | 4.49% |
| SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 4.11% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.09% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.04% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 3.75% |
| NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.26% |
| ZLAB | Zai Lab Ltd | Healthcare | Biotechnology | 3.22% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.21% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.20% |
| ACLX | Arcellx Inc | Healthcare | Biotechnology | 3.20% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 3.08% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.90% |
| LEGN | Legend Biotech Corp | Healthcare | Biotechnology | 2.86% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.74% |
| IDYA | Ideaya Biosciences Inc | Healthcare | Biotechnology | 2.28% |